Cefoxitin
Cefoxitin is a second-generation cephamycin antibiotic developed by Merck & Co., Inc. from Cephamycin C in the year following its discovery, 1972. See also Cefoxitin. Cefoxitin is a beta-lactam antibiotic which binds to penicillin binding proteins, or transpeptidases. By binding to PBPs, cefoxitin prevents the PBPs from forming the cross-linkages between the peptidoglycan layers that make up the bacterial cell wall, thereby interfering with cell wall synthesis. It is a strong beta-lactamase inducer, as are certain other antibiotics (such as imipenem). However, cefoxitin is a better substrate than imipenem for beta-lactamases.[1] (7kcx). . |
|
ReferencesReferences
- ↑ Phillips I, Shannon K. Importance of beta-lactamase induction. Eur J Clin Microbiol Infect Dis. 1993;12 Suppl 1:S19-26. PMID:8477758 doi:10.1007/BF02389873